Nuvalent: Structure-based design to address selectivity, tumor resistance
Emerging Company Profile
Emerging Company Profile: Out of stealth, Deerfield-backed Nuvalent prepares for clinic
Out of stealth, Deerfield-backed Nuvalent prepares for clinical testing.
Jan 27, 2021 | 11:03 AM GMT
After more than three years in stealth mode during which it subsisted on a $50 million series A round from Deerfield, Nuvalent is